MYGN – Myriad Genetics, Inc.

Myriad Genetics, Inc.

MYGN

$4.60

Name : Myriad Genetics, Inc.

Sector : Healthcare

Industry: Diagnostics & Research

Mark. Cap: $430,137,568.00

EPSttm : -3.95

Myriad Genetics, Inc.

$4.60

2.22%

$0.1

MYGN — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

13.15

Margin Of Safety %

Put/Call OI Ratio

0.27

EPS Next Q Diff

EPS Last/This Y

4.01

EPS This/Next Y

0.11

Price

4.5

Target Price

7.39

Analyst Recom

Performance Q

-28.68

Upside

-3,172.2%

Beta

1.83

Ticker: MYGN

16 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-03	MYGN	5.28	0.09	2.74	1708
2026-03-04	MYGN	5.29	0.13	0.24	1775
2026-03-06	MYGN	5.16	0.14	0.00	1785
2026-03-09	MYGN	4.8	0.14	0.00	1791
2026-03-10	MYGN	5.11	0.14	0.05	1765
2026-03-11	MYGN	5.07	0.13	0.58	1817
2026-03-12	MYGN	4.86	0.14	132.00	1835
2026-03-13	MYGN	4.85	0.14	132.00	1835
2026-03-17	MYGN	4.79	0.14	11.00	1858
2026-03-18	MYGN	4.63	0.17	0.00	1892
2026-03-20	MYGN	4.59	0.17	1.00	1986
2026-03-25	MYGN	4.67	0.21	0.00	974
2026-03-26	MYGN	4.62	0.21	0.00	974
2026-03-27	MYGN	4.28	0.22	0.50	1093
2026-03-30	MYGN	4.37	0.22	1.23	1102
2026-03-31	MYGN	4.5	0.27	0.00	1184
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

16 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-02	MYGN	5.01	-108.6	426.0	0.06
2026-03-03	MYGN	5.28	-108.6	425.8	0.06
2026-03-04	MYGN	5.28	-108.6	391.6	0.06
2026-03-05	MYGN	5.14	-108.6	391.4	0.06
2026-03-06	MYGN	5.16	-108.6	391.6	0.06
2026-03-09	MYGN	4.79	-123.7	391.2	0.06
2026-03-10	MYGN	5.11	-123.7	392.0	0.06
2026-03-11	MYGN	5.07	-123.7	391.5	0.06
2026-03-12	MYGN	4.86	-123.7	391.4	0.06
2026-03-13	MYGN	4.67	-123.7	391.4	0.06
2026-03-17	MYGN	4.78	-123.7	391.9	0.06
2026-03-18	MYGN	4.63	-123.7	391.4	0.06
2026-03-19	MYGN	4.76	-123.7	390.1	0.06
2026-03-20	MYGN	4.58	-123.7	389.9	0.06
2026-03-23	MYGN	4.64	-123.7	390.0	0.06
2026-03-24	MYGN	4.60	-123.7	390.0	0.06
2026-03-25	MYGN	4.68	-123.7	390.1	0.06
2026-03-26	MYGN	4.62	-123.7	390.0	0.06
2026-03-27	MYGN	4.29	-123.7	389.7	0.06
2026-03-30	MYGN	4.36	-123.7	389.7	0.06
2026-03-31	MYGN	4.50	-123.7	389.9	0.06
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-02	MYGN	2.35	2.45	12.11
2026-03-03	MYGN	2.35	2.45	12.11
2026-03-04	MYGN	2.35	2.45	12.11
2026-03-05	MYGN	2.35	2.45	12.11
2026-03-06	MYGN	2.35	2.45	12.11
2026-03-09	MYGN	2.35	2.44	12.11
2026-03-10	MYGN	3.28	2.44	12.11
2026-03-11	MYGN	3.28	2.44	13.07
2026-03-12	MYGN	3.28	2.44	13.07
2026-03-13	MYGN	3.28	2.44	13.07
2026-03-18	MYGN	3.28	2.60	13.07
2026-03-19	MYGN	3.28	2.60	13.07
2026-03-20	MYGN	3.28	2.60	13.07
2026-03-23	MYGN	3.28	2.58	13.07
2026-03-24	MYGN	3.28	2.58	13.07
2026-03-25	MYGN	3.28	2.58	13.15
2026-03-26	MYGN	3.28	2.58	13.15
2026-03-27	MYGN	3.28	2.58	13.15
2026-03-30	MYGN	3.28	2.60	13.15
2026-03-31	MYGN	3.28	2.60	13.15
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

0.02

Avg. EPS Est. Current Quarter

-0.07

Avg. EPS Est. Next Quarter

0.02

Insider Transactions

3.28

Institutional Transactions

2.6

Beta

1.83

Average Sales Estimate Current Quarter

202

Average Sales Estimate Next Quarter

215

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

87.8

Max Drawdown 5-Year %

-89.5

Target Price

7.39

P/E

Forward P/E

31.37

PEG

0.53

P/S

0.51

P/B

1.14

P/Free Cash Flow

EPS

-3.95

Average EPS Est. Cur. Y

0.06

EPS Next Y. (Est.)

0.17

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-44.38

Relative Volume

0.73

Return on Equity vs Sector %

-126.9

Return on Equity vs Industry %

-110.5

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.01

EBIT Estimation

389.9

◆ MYGN Healthcare

$4.50

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

0/20

Pullback

16/25

Volume

9/15

Valuation

15/20

TP/AR

0/10

Options

8/10

RSI

43.1

Range 1M

19.5%

Sup Dist

5.6%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

0/25

Growth

13/30

Estimates

0/20

Inst/Vol

4/15

Options

6/10

EPS Yr

-24.6%

EPS NY

217.2%

52W%

13.1%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +41.3% upside

Quality

6/30

Valuation

14/30

Growth

12/25

Stability

7/10

LT Trend

1/5

Upside

+41.3%

Quality

Myriad Genetics, Inc.

Sector: Healthcare

Industry: Diagnostics & Research

Employees: 2700

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children's Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

MYGN

Latest News

—

Caricamento notizie per MYGN…

stock quote shares MYGN – Myriad Genetics, Inc. Stock Price stock today

news today MYGN – Myriad Genetics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch MYGN – Myriad Genetics, Inc. yahoo finance google finance

stock history MYGN – Myriad Genetics, Inc. invest stock market

stock prices MYGN premarket after hours

ticker MYGN fair value insiders trading

MYGN – Myriad Genetics, Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: MYGN

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y